New cancer drug trial halted early – what we know

NCT ID NCT06779851

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The main goals were to check safety, find the right dose, and see if the drug shrinks tumors. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carolina BioOncology Institute

    Huntersville, North Carolina, 28078, United States

  • Hackensack Meridian John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Honor Health Research Institute

    Scottsdale, Arizona, 85260, United States

  • Providence Cancer Institute

    Portland, Oregon, 97213, United States

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas, 78229, United States

  • Start Midwest

    Grand Rapids, Michigan, 49546, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States